Figure 2.

NASH features are antagonized by cholestyramine treatment. The liver tissues and serum ALT levels of the mice described in Fig. 1 were assessed for NASH characteristics. A: Hematoxylin-eosin (H&E) staining. B: Hepatic steatosis and lesions were assessed for NASH based on H&E staining. C: Masson’s trichrome staining for liver fibrosis. D: Hepatic gene expression of Coll-α1, n = 6–7. E and F: Immunohistochemical staining of T-cell marker CD3 of liver tissue. CD3⁺ cell number counting on liver tissue stained with CD3 (×400-fold). Liver inflammation as measured by gene expression of TNF-α (G), arginase 1 (H), and iNOS (I), n = 4–6. J: Serum ALT levels, n = 8–10. *P < 0.05; **P < 0.01; ***P < 0.001. * and **Comparisons were made against the HD group. # and ##Comparisons were made against the HD+CHOL group. Data were mean ± SEM. Ctrl, control.